Enterprise Value
264.8M
Cash
175.3M
Avg Qtr Burn
-29.35M
Short % of Float
9.98%
Insider Ownership
0.78%
Institutional Own.
86.41%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ganaxolone (ZTALMY) Details Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder | Approved Quarterly sales | |
Ganaxolone Details Tuberous sclerosis complex | Phase 3 Data readout | |
Phase 3 Data readout | ||
Ganaxolone Details Established Status Epilepticus | Phase 2 Data readout | |
Second generation formulation Details Lennox-Gastaut syndrome | Phase 1 Data readout |